OncoMatch/Clinical Trials/NCT07098338
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Is NCT07098338 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Rilvegostomig and Ramucirumab for non-small cell lung cancer.
Treatment: Rilvegostomig · Ramucirumab · Dato-DXd — This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) tumor cell expression ≥ 50% (TC ≥ 50%)
PD-L1 TC ≥ 1% (TC≥ 50% for sub-study 1, 1-49% for sub-study 2)
Required: PD-L1 (CD274) tumor cell expression 1-49% (TC 1-49%)
PD-L1 TC ≥ 1% (TC≥ 50% for sub-study 1, 1-49% for sub-study 2)
Required: EGFR sensitizing mutation
Absence of sensitizing EGFR mutations
Required: ALK rearrangement
Absence of ... ALK rearrangements
Disease stage
Metastatic disease required
Performance status
WHO/ECOG 0–1
Prior therapy
Must have received: targeted therapy
had progressed on prior targeted therapy
Cannot have received: systemic chemotherapy
Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2.
Cannot have received: chemoradiation
Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2.
Cannot have received: immunotherapy
Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2.
Cannot have received: immune-mediated therapy
Prior exposure to immune-mediated therapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Santa Monica, California
- Research Site · Santa Rosa, California
- Research Site · Atlanta, Georgia
- Research Site · Baltimore, Maryland
- Research Site · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07098338 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic chemotherapy, chemoradiation, immunotherapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 tumor cell expression ≥ 50% is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 tumor cell expression 1-49% is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify